Lack of association between functional polymorphism of DNA repair genes (XRCC1, XPD) and clinical response in Indian chronic myeloid leukemia patients
- 10 Downloads
The resistance for the tyrosine kinase inhibitors in chronic myeloid leukemia (CML) occurs mainly due to BCR/ABL1 dependent and independent mechanisms. The defective DNA repair due to functional polymorphisms in DNA repair genes, might act as an etiological factor for leukemia progression. The study was carried out to understand the role of DNA repair genes (XRCC1, XPD) polymorphisms in Imatinib mesylate (IM) resistant CML patients. The study was carried out in total 87 CML patients (43 nonresponders-cases and 44 responders) who were treated with Imatinib. The treatment and follow-up was done according to European LeukemiaNet guidelines. The genotyping of selected SNPs were studied using RFLP and confirmed with Sanger sequencing (20%). The statistical analysis was performed using online tools (Socscistatistics and GraphPad InStat software). In our study no significant association was inferred between genotypes of DNA repair genes (XRCC1; rs1799782, rs25487, and XPD; rs13181) and complete cytogenetic response as well as molecular response. However there might be a possibility of association between XRCC1 Arg399Gln genotype AA/GA and cytogenetic response though it is statistically insignificant (p > 0.05). Though none of the genotypes of the DNA repair genes showed association with IM response, near association between XRCC1Arg399Gln genotype and cytogenetic response observed in our study. Hence, large sample size should be studied to establish the association of SNPs of DNA repair genes and IM response. Our study is a novel and important to explain the role of DNA repair genes polymorphisms in IM resistance.
KeywordsDNA repair genes Double strand break (DSB) Clinical response Single nucleotide polymorphisms (SNPs) Chronic myeloid leukemia (CML) Imatinib mesylate
The study was carried out from Institutional core grant from Indian Council of Medical Research, India. Thanks also due to study participants for their participation in follow up studies.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Deligezer U, Akisik EE, Dalay N (2007) Lack of association of XRCC1 codon 399Gln polymorphism with chronic myelogenous leukemia. Anticancer Res 27:2453–2456Google Scholar
- 9.Wang LJ, Wang HT, Wang XX (2016) Association of XRCC1 gene polymorphisms and pancreatic cancer risk in a Chinese population. Genet Mol Res 15(2):1–7Google Scholar
- 11.Branford S, Rudzki Z, Walsh S et al (2003) Detection of BCR-ABL mutations in patients with treated with Imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate binding loop (P-loop) are associated with a poor prognosis. Blood 102(1):276–283CrossRefGoogle Scholar
- 16.Le Coutre P, Tassi E, Varella-Garcia M et al (2000) Induction of resistance to Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95:1758–1766Google Scholar
- 21.Salimizand H, Amini S, Abdi M, Ghaderi B, Azadi NA (2016) Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with Imatinib mesylate in patients with chronic myeloid leukemia. Tumour Biol 37(1):791–798CrossRefGoogle Scholar
- 22.Wang F, Zhao Q, He HR, Zhai YJ, Lu J, Hu HB, Zhou JS, Yang YH, Li YJ (2015) The association between XRCC1 Arg399Gln polymorphism and risk of leukemia in different populations: a meta-analysis of case-control studies. Onco Targets Ther 8:3277–3287Google Scholar